Respiratory Syncytial Virus Infections Clinical Trial
Official title:
Testing of Respiratory Specimens for the Validation of the QIAGEN ResPlex II Advanced Panel Test and the Artus Influenza A/B RT-PCR Test
The study will be conducted using nasopharyngeal swab specimens collected prospectively from individuals suspected of having the signs and symptoms of an acute respiratory tract infection caused by a respiratory virus. A series of standard viral culture tests validated for routine use in the clinical laboratory, and/or a series of PCR-based Laboratory Developed Tests (PCR-LDT) validated by a central reference laboratory will be used to verify the performance of the investigational artus Influenza A/B RT-PCR test and the QIAGEN ResPlex II Advanced Panel test. From each specimen five (5) aliquots will be prepared: (a) one aliquot will be tested in real-time using the assigned viral culture reference methods; (b) one aliquot will be used to extract nucleic acid in real-time for investigational testing; (c) one aliquot of the specimen will be stored at --70C for subsequent shipment to the reference laboratory for PCR-LDT testing, (d) one aliquot will be archived at -70C for subsequent follow-up by the reference laboratory (e.g., bi-directional sequencing of positive specimens), and (e) any remaining specimen will be stored for the Fresh vs. Frozen Study. The extracted nucleic acid generated from the second aliquot (i.e., "b" above) will be split and subjected to testing by both the artus Influenza A/B RT-PCR test and the ResPlex II Advanced Panel test.
Each year the morbidity and mortality associated with acute respiratory tract infections
fluctuates seasonally. This rise and fall is associated with the changing prevalence of
respiratory viruses in the population. Myriad respiratory viruses are responsible for these
infections. For example, Influenza Virus, Respiratory Syncytial Virus (RSV), Parainfluenza
Virus, Human Metapneumovirus, Rhinovirus, and Adenovirus have all been identified as causing
such acute infections. Numerous pathogenic subtypes have been identified within most of
these viral groups. The outbreak of Severe Acute Respiratory Syndrome (SARS) in 2003 was
eventually identified as a Coronavirus; the mortality of SARS among the elderly can be as
high as 50%. More recently, Human Bocavirus (HBoV) has also been identified as causing acute
respiratory tract infections. In 2005 the HBoV was identified by molecular testing and was
found to be the only virus identified in a subpopulation of patients suffering from
respiratory tract infections. Apart from supportive measure (e.g., bed rest, hydration,
etc.), there are no effective treatments for many of these viral infections; however,
antiviral agents (e.g., the neuraminidase inhibitors oseltamivir or zanamivir) can be used
to alleviate the severity of flu-like symptoms. Identification of a respiratory virus as the
causative agent is important because it eliminates the need for treatment with antibiotics;
physicians typically wait 7-10 days for symptoms to alleviate before prescribing antibiotics
due to risks associated with exacerbating bacterial antibiotic resistance.
Each year the virus population fluctuates, and with it the antigenic presentation of the
dominant strains that circulate through the population. Epidemics arise when larger and
larger portions of the population do not have innate or acquired immunological resistance to
such strain(s) in a given season. The World Health Organization (WHO) maintains a separate
website dedicated to tracking outbreaks of influenza, especially avian influenza
(https://www.who.int/fluvirus_tracker). These zoonotic transmissions that further adapt to
enable human-to-human transmission are of the greatest concern because it is predicted that
virtually all humans will be immunologically naïve. Zoonotic transmissions in the human
population are monitored in the hope that a pandemic similar to the Spanish Flu of 1918 can
be avoided; it is estimated that well over 25 million people died from the Spanish Flu. The
United States government also maintains a separate website with resources regarding the flu
and pandemic related information (http://www.pandemicflu.gov/). On June 11, 2009 the WHO
raised the pandemic threat level to 6 in response to the global appearance of a new strain
of swine Influenza A (subtype H1N1). The rapidity with which the H1N1 virus has spread
exemplifies the notion that quickly and accurately identifying a viral pathogen associated
with an outbreak is critical to global public health.
In addition to the threat of an influenza outbreak, the expansion in the number of viruses
that cause acute respiratory tract infections compounds the difficulty in correctly and
rapidly identifying the primary pathogen; each new virus or subtype increases the complexity
of testing. Molecular diagnostic assays are ideally suited to address this complexity.
Assays based on the polymerase chain reaction (PCR) can incorporate multiple primers and
probes (e.g., multiplexed) in a single reaction to deal with this complexity.4 Such assays
are extremely sensitive, have a high degree of specificity, and can be performed very
quickly. The artus Influenza A/B RT-PCR test is a real-time PCR assay for the detection and
identification of Influenza A and B, while the QIAGEN ResPlex II Advanced Panel test is a
nucleic acid amplification-based assay for the detection and identification of a broad range
of some of the most common respiratory viruses associated with acute respiratory tract
infections. In the present study respiratory specimens will be prospectively collected and
tested using the artus Influenza A/B RT-PCR test and the QIAGEN ResPlex II Advanced Panel
test.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03698084 -
RESCEU: Defining the Burden of RSV Disease
|
||
Completed |
NCT04090658 -
A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults
|
Phase 1 | |
Completed |
NCT04231968 -
A Study of AK0529 in Chinese Infants Hospitalized With RSV
|
Phase 3 | |
Completed |
NCT03227029 -
Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age
|
Phase 1 | |
Completed |
NCT02984280 -
Specific Respiratory Infections as Triggers of Acute Medical Events
|
N/A | |
Withdrawn |
NCT02864628 -
RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.
|
Phase 1 | |
Completed |
NCT02873286 -
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
|
Phase 2 | |
Terminated |
NCT02948127 -
Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
|
Phase 1 | |
Completed |
NCT02247726 -
RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.
|
Phase 2 | |
Completed |
NCT02040831 -
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 | |
Completed |
NCT02237209 -
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 | |
Completed |
NCT01915394 -
Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial)
|
N/A | |
Completed |
NCT01355016 -
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00232635 -
A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT
|
Phase 2 | |
Completed |
NCT01155193 -
Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany
|
||
Not yet recruiting |
NCT06083623 -
A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants
|
Phase 2/Phase 3 | |
Terminated |
NCT02890381 -
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age
|
Phase 1 | |
Active, not recruiting |
NCT03422237 -
Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants and Children 6 to 24 Months of Age
|
Phase 1 | |
Completed |
NCT03674177 -
A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women
|
Phase 1 | |
Completed |
NCT01968083 -
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 |